In this valuable study, through carefully executed and rigorously controlled experiments, the authors challenged a previously reported role of the Death Receptor 6 (DR6/Tnfrsf21) in Wallerian ...

Emalex Biosciences’ Expanded Access Programme for investigational Tourette syndrome drug, ecopipam receives US FDA authorization: Chicago Friday, October 10, 2025, 18:00 Hrs [IS ...

Leaving the house one wet morning this week, I noticed our maples had shed many more of their leaves overnight. Despite ...

On a Saturday evening in June, people of this rural region gathered at the historic Lee Theatre to celebrate the founding of ...

The opioid painkiller tramadol does little to reduce moderate to severe pain, according to results published Oct. 7 in the ...

Emalex received FDA authorization for an Expanded Access Program for its investigational Tourette syndrome drug. New Drug ...

The fall, 2025 version of the County Health Fair will take place on Saturday, Oct. 11, from 7 a.m. to 11 a.m., at Hope ...

Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of ...

Aspartame is considered safe within daily limits, yet researchers are studying whether it may affect tardive dyskinesia. Here ...

Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing ...

Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.